12 March 2020

Sofitel Legend Amsterdam The Grand

2020 Presenting Companies

Aelin Therapeutics (BEL)

Aelin Therapeutics will exploit its proprietary Pept-in™ protein knockdown platform as a novel modality in drug development. The company is based on a very comprehensive preclinical package illustrating different applications of the technology (in bacteria, fungi, viruses, cancer cells). The technology is furthermore protected by a strong and growing IP portfolio.

www.aelintx.com

Alize Pharma
AM-Pharma (NL)

AM-Pharma is a biopharmaceutical company, engaged in the development of novel human alkaline phosphatase therapeutics for unmet needs in severe inflammatory diseases.  The Company’s lead programs for this therapeutic enzyme are in Acute Kidney Injury and Inflammatory Bowel Disease.

Artios Pharma (UK)

Since its foundation Artios has grown into a leading biotech company with an exciting pipeline of assets, a world class R&D team with a strong track record in translating DDR and other oncology projects from research to the clinic, and an enviable cash position following two successful fundraises from high calibre investors.

Arvelle Therapeutics (SWZ)

  • Arvelle was formed with the mission of bringing innovative solutions to patients suffering from CNS disorders.
  • Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market.
  • Arvelle will be based in Switzerland
Atlantic Therapeutics
BioArtic
Cardior Pharmaceuticals (GER)

_cardior

 

Cardior is a privately held biopharmaceutical company founded by Prof. Thomas Thum out of the Hannover Medical School. The company is dedicated to becoming world-leader in design, research and development of non-coding RNA-based therapeutics for cardiovascular diseases. Cardior aims to market its products in collaboration with a strategic pharma-partner after clinical validation.

www.cardior.de

Celyad (BEL)

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01, is currently being evaluated in a Phase I dose escalation clinical trial.

Cergentis
Eloxx Pharmaceuticals (ISR)

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have short half-life messenger RNA that produce truncated, nonfunctional proteins, accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 2,000 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and enabling protein synthesis to continue through the premature stop codons to restore protein functionality. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis cystinosis. ELX-02 has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA. with R&D operations in Rehovot, Israel.

eTheRNA (BEL)

eTheRNA is a clinical stage immunotherapy company developing mRNA based therapeutic products for the treatment of cancer. To date the Company has completed 4 clinical studies and has 2 studies underway currently. The company has built a new GMP facility which also provides contract manufacturing services.

www.etherna.be

Evotec AG (GER)

Evotec is a drug discovery company focused on rapidly progressing innovative product approaches with its customers. It operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target identification to IND-enabling studies and high-end CMC (Chemistry, manufacturing and controls). The Company focuses on key therapeutic areas including neuronal diseases, diabetes and diabetic complications, oncology, pain, anti-infectives, respiratory and fibrosis.

For additional information please go to www.evotec.com.

FoRx
Galapagos (NL)

Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Galapagos’ pipeline comprises Phase 3 through to discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. Our target discovery platform has delivered three novel mechanisms showing promising patient results in, respectively, inflammatory diseases, idiopathic fibrosis and atopic dermatitis. Galapagos is focused on the development and commercialization of novel medicines that will improve people’s lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 578 employees, operating from its Mechelen, Belgium headquarters and facilities in the Netherlands, France, and Croatia. More information at www.glpg.com.

GTX medical (NL)

GTX Medical (Eindhoven, The Netherlands; Lausanne, Switzerland) is a clinical-stage medical device company developing a new therapy to help paralyzed people walk again, using a new form of Spinal Cord Stimulation: Targeted Epidural Spinal Stimulation (TESS), in combination with intensive rehabilitation training. GTX medical is a spinout of the group of Prof Courtine at the Center for Neuroprosthetics at the Swiss Federal Institute of Technology Lausanne (EPFL).

Heidelberg Pharma
ImCheck (FRA)

ImCheck Therapeutics is a Marseille-based, privately-held biotech company developing nenext-generationmmuno-modulatory antibodies acting on both adaptive and innate immunity for the treatment of cancer and other immune related diseases.

With a “precision medicine-based” translational approach and several established academic collaborations, ImCheck is uniquely positioned to develop the right therapy for each patient.

ImCyse (BEL)

 

istar Medical
Kiadis Pharma (NL)

Kiadis

Kiadis allodepleted T-cell immunotherapy product can make haploidentical hematopoietic stem cell transplantations safer and more effective. Phase 2 data with lead product ATIR given after HSCT in blood cancer patients shows a clinically relevant improvement over literature for the Baltimore protocol, without risk of severe chronic Graft versus Host Disease.

www.kiadis.com

Lumeon (UK)

 

Lumeon Care Pathway Management platform enables healthcare organizations orchestrate and automate systems, processes and teams – uniting patients with care teams: improving patient experience; providing better, more consistent outcomes; ensuring care is efficiently coordinated in real-time. CPM enables digital control of care delivery models, maximizing resource utilization, reducing cost and minimizing variation.

Merus (NL)


 

 

Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways

www.merus.nl

Neurent Medical
Nouscom
Oncopeptides

 

 

OneProjects

 

Orphazyme A/S (DEN)

Orphazyme’s current clinical programs investigate arimoclomol as a treatment for four protein-misfolding indications: The protein-aggregation diseases Amyotrophic Lateral Sclerosis (ALS) and sporadic Inclusion Body Myositis (sIBM), and the lysosomal storage diseases Niemann-Pick disease Type C (NPC) and Gaucher disease. The new molecular entity (NME) program focuses on the development of new molecules as a treatment for rele- vant protein-misfolding diseases.

OxThera AB (SWE)

 

 

OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a fatal ultra-orphan disease in children, and where there are currently no available therapies. The company has initiated a pivotal Phase III study in PH with Oxabact in order to stop and/or delay disease progression. Oxabact holds orphan drug designations in the EU and the US for the treatment of PH, and in the EU for treatment of Short Bowel Syndrome (SBS).

www.oxthera.com

Pharming
Pharvaris (NL)
Pharvaris is a preclinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. The company reunites the core team responsible for the discovery and approval of the HAE treatment FIRAZYR icatibant.  PHA121 is a potent and orally available novel small molecule targeting this clinically proven therapeutic target, with clinical entry anticipated in the near-term.

 

Quantib
Safeheal
SNIPR Biome (DEN)

SNIPR BIOME is engaged in the discovery and development of CRISPR/Cas-based drugs, using its proprietary and patent-protected CRISPR/Cas platform. SNIPR BIOME is pioneering a novel use of CRISPR/Cas technology to selectively and precisely eradicate target bacteria, while leaving the rest of the patient’s microbial community intact.

Vetex Medical (IRE)

Vetex Medical is a privately-held early stage company based in the strong Med Tech Cluster in Galway Ireland. Established in 2016, the company is focused on making venous clot removal predictable, quick and cost-effective. The company’s first thrombectomy product treats deep vein thrombus by removing large volumes of clot in a single session, without use of thrombolytic drugs.

ViCentra (NL)
Vivasure Medical (IRE)

vivasure-logo-150x90

In percutaneous endovascular procedures such as heart valve replacement and aortic aneurysm repair, large arteriotomies are created. Existing percutaneous closure technologies are complex to use, are associated with significant complications and leave permanent implants in the vessel. Vivasure solves this problem with a safe, effective and easy-to-use device.

www.vivasuremedical.com

Vivoryon
uniQure (NL)

uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular technology platform to rapidly bring new disease-modifying therapies to patients with severe genetic diseases.

We are advancing a focused pipeline of innovative gene therapies and have established clinical proof-of-concept in our lead indication, hemophilia B, and preclinical proof-of-concept in Huntington’s disease. Our pipeline of adeno-associated virus (AAV)-based gene therapies has been developed using an innovative technology platform, supported by industry-leading proprietary commercial-grade manufacturing capabilities.

www.uniqure.com

Xeltis (NL)

Xeltis ETR technology has been tested in various cardiovascular feasibility clinical trials (Fontan, Atrial patch and Pulmonary valve). Xeltis closed a Series B financing and an extension based on these first promising clinical results. In 2017 the company closed a round of 45 M to further expand applications in the cardiovascular space.   

Event organised by

Sponsors 2020